FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141110588> ?p ?o ?g. }

• W2141110588 abstract "Recent studies in mice, nonhuman primates, and clinical trials in human patients have emphasized the importance of the persistence of the vaccine-induced immune response, immunological memory, in mediating protective immunity against infectious diseases and cancer. Multiple extrinsic pathways control the differentiation of CD8+ cytotoxic T lymphocytes (CTL) into effector or memory cells by regulating the balanced expression of intracellular mediators in the antigen-activated T cells. Notably, inhibition of mediators of effector differentiation like mTOR, GSK3β or T-bet using genetic means or whenever available pharmacological agents, not only prevented the accumulation of the short-lived effectors but also redirected the activated T cells to differentiate along the memory pathway. For example, pharmacological inhibition of mTOR or GSK3β in mice with rapamycin or TSW119, respectively, led to the differentiation of antigen activated CD8+ T cells into long lasting memory cells that exhibited enhanced antiviral and antitumor immunity. Nevertheless, pharmacological agents often exhibit undesirable effects reflecting the broad distribution of their targets. For example, rapamycin inhibition of mTOR promotes the development of immune suppressive regulatory CD4+ T cells and GSK3β; inhibition polarizes dendritic cells (DC) to a tolerogenic state, arguably counterproductive in the setting of vaccination. In addition, development of pharmacological agents to modulate the function of intracellular targets that are not accessible to antibodies (“undruggable targets”) is highly challenging, and their availability especially for clinical use is limited.Here we describe a versatile, broadly applicable, and clinically feasible approach to promote the generation of memory T cell responses that addresses the main limitations of pharmacological agents. RNAi was used to downregulate intracellular mediators of effector differentiation that were targeted to CD8+ T cells by conjugation to aptamer ligands. We have shown that a CD8+ T cell targeted 4-1BB aptamer-raptor siRNA conjugate administered to mice by tail vein injection downregulated mTORC1, while preserving mTORC2, activity in at least 60% of adoptively transferred OVA-specific transgenic OT-I cells while sparing host cells. Both rapamycin and aptamer-siRNA conjugate led to the development of an enhanced memory response in mice as judged by the ability of the memory cells to proliferate in response to re-exposure to antigen at a latter time point. However, the rapamycin generated CTL were defective in their cytotoxic effector functions and failed to elicit protective immunity against a tumor challenge. In contrast, the aptamer-raptor siRNA generated CTL exhibited normal cytotoxic effector functions and enhanced vaccine-induce protective antitumor immunity in both prophylactic and therapeutic tumor models. Reflecting the lack of cell specificity of mTOR inhibition by rapamycin, and providing a potential mechanisms underlying the effector defect of rapamycin generated CTL, dendritic cells from mice treated with rapamycin, but not with aptamer-raptor siRNA conjugate, exhibited reduced MLR activity, consistent with the known suppressive effects of rapamycin induced mTOR inhibition on DC.These studies demonstrate the feasibility and efficiency of aptamer targeted delivery of siRNAs to immune cells, and underscore the potential advantages of aptamer-targeted siRNA delivery over nontargeted administration of pharmacological agents.Citation Format: Alexey Berezhnoy, Iris Castro, Agata Levay, Thomas Malek, Eli Gilboa. Aptamer-targeted siRNA-mediated inhibition of mTORC1 in antigen-primed CD8+ cytotoxic T lymphocytes enhances immunological memory and antitumor immunity. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B68." @default.
• W2141110588 created "2016-06-24" @default.
• W2141110588 creator A5018590594 @default.
• W2141110588 creator A5023066544 @default.
• W2141110588 creator A5065361211 @default.
• W2141110588 creator A5068892519 @default.
• W2141110588 creator A5070692584 @default.
• W2141110588 date "2013-01-01" @default.
• W2141110588 modified "2023-09-27" @default.
• W2141110588 title "Abstract B68: Aptamer-targeted siRNA-mediated inhibition of mTORC1 in antigen-primed CD8+ cytotoxic T lymphocytes enhances immunological memory and antitumor immunity." @default.
• W2141110588 doi "https://doi.org/10.1158/1538-7445.tumimm2012-b68" @default.
• W2141110588 hasPublicationYear "2013" @default.
• W2141110588 type Work @default.
• W2141110588 sameAs 2141110588 @default.
• W2141110588 citedByCount "0" @default.
• W2141110588 crossrefType "proceedings-article" @default.
• W2141110588 hasAuthorship W2141110588A5018590594 @default.
• W2141110588 hasAuthorship W2141110588A5023066544 @default.
• W2141110588 hasAuthorship W2141110588A5065361211 @default.
• W2141110588 hasAuthorship W2141110588A5068892519 @default.
• W2141110588 hasAuthorship W2141110588A5070692584 @default.
• W2141110588 hasConcept C147483822 @default.
• W2141110588 hasConcept C154317977 @default.
• W2141110588 hasConcept C167672396 @default.
• W2141110588 hasConcept C193419808 @default.
• W2141110588 hasConcept C202751555 @default.
• W2141110588 hasConcept C203014093 @default.
• W2141110588 hasConcept C2779341262 @default.
• W2141110588 hasConcept C502942594 @default.
• W2141110588 hasConcept C51785407 @default.
• W2141110588 hasConcept C55493867 @default.
• W2141110588 hasConcept C62478195 @default.
• W2141110588 hasConcept C86554907 @default.
• W2141110588 hasConcept C86803240 @default.
• W2141110588 hasConcept C8891405 @default.
• W2141110588 hasConcept C95444343 @default.
• W2141110588 hasConcept C98490376 @default.
• W2141110588 hasConceptScore W2141110588C147483822 @default.
• W2141110588 hasConceptScore W2141110588C154317977 @default.
• W2141110588 hasConceptScore W2141110588C167672396 @default.
• W2141110588 hasConceptScore W2141110588C193419808 @default.
• W2141110588 hasConceptScore W2141110588C202751555 @default.
• W2141110588 hasConceptScore W2141110588C203014093 @default.
• W2141110588 hasConceptScore W2141110588C2779341262 @default.
• W2141110588 hasConceptScore W2141110588C502942594 @default.
• W2141110588 hasConceptScore W2141110588C51785407 @default.
• W2141110588 hasConceptScore W2141110588C55493867 @default.
• W2141110588 hasConceptScore W2141110588C62478195 @default.
• W2141110588 hasConceptScore W2141110588C86554907 @default.
• W2141110588 hasConceptScore W2141110588C86803240 @default.
• W2141110588 hasConceptScore W2141110588C8891405 @default.
• W2141110588 hasConceptScore W2141110588C95444343 @default.
• W2141110588 hasConceptScore W2141110588C98490376 @default.
• W2141110588 hasLocation W21411105881 @default.
• W2141110588 hasOpenAccess W2141110588 @default.
• W2141110588 hasPrimaryLocation W21411105881 @default.
• W2141110588 hasRelatedWork W136811303 @default.
• W2141110588 hasRelatedWork W1508828624 @default.
• W2141110588 hasRelatedWork W1951081312 @default.
• W2141110588 hasRelatedWork W2117636996 @default.
• W2141110588 hasRelatedWork W2147184466 @default.
• W2141110588 hasRelatedWork W2155533003 @default.
• W2141110588 hasRelatedWork W2303410532 @default.
• W2141110588 hasRelatedWork W2339658610 @default.
• W2141110588 hasRelatedWork W2469703794 @default.
• W2141110588 hasRelatedWork W2501578153 @default.
• W2141110588 hasRelatedWork W2547595918 @default.
• W2141110588 hasRelatedWork W2571096312 @default.
• W2141110588 hasRelatedWork W2734345862 @default.
• W2141110588 hasRelatedWork W2914688662 @default.
• W2141110588 hasRelatedWork W2963070159 @default.
• W2141110588 hasRelatedWork W2966573381 @default.
• W2141110588 hasRelatedWork W2984499287 @default.
• W2141110588 hasRelatedWork W3013885917 @default.
• W2141110588 hasRelatedWork W3119209177 @default.
• W2141110588 hasRelatedWork W3096232019 @default.
• W2141110588 isParatext "false" @default.
• W2141110588 isRetracted "false" @default.
• W2141110588 magId "2141110588" @default.
• W2141110588 workType "article" @default.